Advertisement

Intermittent Chemotherapy with Docetaxel for Metastatic Castration-Resistant Prostate Cancer

  • Shintaro NaritaEmail author
  • Tomonori Habuchi
Chapter

Abstract

The optimal schedule of docetaxel chemotherapy for castration-resistant prostate cancer is unknown, although continuous administration is accepted as the standard. However, several disadvantages, including side effects, costs, and development of resistant clones, need to be considered during continuous administration of docetaxel. Intermittent docetaxel therapy represents an appealing option to address these issues. Previous studies have reported that intermittent docetaxel therapy is associated with favorable outcomes, with successful chemotherapy holidays and maintained Quality of Life (QOL). However, limitations of these studies include a wide variation in study design and schedule and a lack of randomized trials comprising a large number of patients allowing comparison of outcomes with continuous administration. This chapter summarizes current data on intermittent docetaxel therapy in androgen-independent and castration-resistant prostate cancer from previous literature and examines future directions regarding the use of this strategy as a therapeutic option for advanced prostate cancer.

Keywords

Castration-resistant prostate cancer Chemotherapy Docetaxel Intermittent Metastasis 

References

  1. 1.
    Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.CrossRefGoogle Scholar
  2. 2.
    Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20.CrossRefGoogle Scholar
  3. 3.
    Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242–5.CrossRefGoogle Scholar
  4. 4.
    Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46.CrossRefGoogle Scholar
  5. 5.
    James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77.CrossRefGoogle Scholar
  6. 6.
    Klil-Drori AJ, Azoulay L, Pollak MN. Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? Nat Rev Clin Oncol. 2017;14(2):85–99.CrossRefGoogle Scholar
  7. 7.
    Miyake H, Sakai I, Terakawa T, Harada K, Fujisawa M. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer. Urol Oncol. 2013;31(6):733–8.CrossRefGoogle Scholar
  8. 8.
    Gyawali B, Koomulli-Parambil S, Iddawela M. Continuous versus intermittent docetaxel for metastatic castration resistant prostate cancer. Crit Rev Oncol Hematol. 2016;102:118–24.CrossRefGoogle Scholar
  9. 9.
    De Souza R, Zahedi P, Moriyama EH, Allen CJ, Wilson BC, Piquette-Miller M. Continuous docetaxel chemotherapy improves therapeutic efficacy in murine models of ovarian cancer. Mol Cancer Ther. 2010;9(6):1820–30.Google Scholar
  10. 10.
    Chen CS, Doloff JC, Waxman DJ. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression. Neoplasia. 2014;16(1):84–96.CrossRefGoogle Scholar
  11. 11.
    Muss HB, Case LD, Richards F 2nd, White DR, Cooper MR, Cruz JM, et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The piedmont oncology association. N Engl J Med. 1991;325(19):1342–8.CrossRefGoogle Scholar
  12. 12.
    Maughan TS, James RD, Kerr DJ, Ledermann JA, Seymour MT, Topham C, et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet. 2003;361(9356):457–64.CrossRefGoogle Scholar
  13. 13.
    Gerber DE, Schiller JH. Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J Clin Oncol. 2013;31(8):1009–20.CrossRefGoogle Scholar
  14. 14.
    Magnan S, Zarychanski R, Pilote L, Bernier L, Shemilt M, Vigneault E, et al. Intermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. JAMA Oncol. 2015;1(9):1261–9.CrossRefGoogle Scholar
  15. 15.
    Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer. 2003;89(6):968–70.CrossRefGoogle Scholar
  16. 16.
    Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer. 2004;91(8):1425–7.CrossRefGoogle Scholar
  17. 17.
    Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, et al. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer. 2008;112(2):326–30.CrossRefGoogle Scholar
  18. 18.
    Soga N, Kato M, Nishikawa K, Hasegawa Y, Yamada Y, Kise H, et al. Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients. Int J Clin Oncol. 2009;14(2):130–5.CrossRefGoogle Scholar
  19. 19.
    Mountzios I, Bournakis E, Efstathiou E, Varkaris A, Wen S, Chrisofos M, et al. Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer. Urology. 2011;77(3):682–7.CrossRefGoogle Scholar
  20. 20.
    Narita S, Tsuchiya N, Yuasa T, Maita S, Obara T, Numakura K, et al. Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer. Int J Clin Oncol. 2012;17(3):204–11.CrossRefGoogle Scholar
  21. 21.
    Li YF, Zhang SF, Zhang TT, Li L, Gan W, Jia HT, et al. Intermittent tri-weekly docetaxel plus bicalutamide in patients with castration-resistant prostate cancer: a single-arm prospective study using a historical control for comparison. Asian J Androl. 2013;15(6):773–9.CrossRefGoogle Scholar
  22. 22.
    Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, et al. Intermittent chemotherapy as a platform for testing novel agents in patients with metastatic castration-resistant prostate cancer: a department of defense prostate cancer clinical trials consortium randomized phase II trial of intermittent docetaxel with prednisone with or without maintenance GM-CSF. Clin Genitourin Cancer. 2015;13(3):e191–8.CrossRefGoogle Scholar
  23. 23.
    Caffo O, Lo Re G, Sava T, Buti S, Sacco C, Basso U, et al. Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients. Future Oncol. 2015;11(6):965–73.CrossRefGoogle Scholar
  24. 24.
    Kume H, Kawai T, Nagata M, Azuma T, Miyazaki H, Suzuki M, et al. Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer. Mol Clin Oncol. 2015;3(2):303–7.CrossRefGoogle Scholar
  25. 25.
    Narita S, Koie T, Yamada S, Orikasa K, Matsuo S, Aoki H, et al. A prospective multicenter study of intermittent chemotherapy with docetaxel and prednisolone for castration-resistant prostate cancer. Jpn J Clin Oncol. 2016;46(6):547–53.CrossRefGoogle Scholar
  26. 26.
    Huang M, Narita S, Numakura K, Tsuruta H, Saito M, Inoue T, et al. A high-fat diet enhances proliferation of prostate cancer cells and activates MCP-1/CCR2 signaling. Prostate. 2012;72(16):1779–88.CrossRefGoogle Scholar
  27. 27.
    Abdollah F, Sood A, Sammon JD, Hsu L, Beyer B, Moschini M, et al. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients. Eur Urol. 2015;68(3):497–505.CrossRefGoogle Scholar
  28. 28.
    Matsuyama H, Shimabukuro T, Hara I, Kohjimoto Y, Suzuki K, Koike H, et al. Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer. Int J Clin Oncol. 2014;19(5):946–54.CrossRefGoogle Scholar
  29. 29.
    Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.CrossRefGoogle Scholar
  30. 30.
    Rexer H. AUO study in hormone-refractory prostate cancer. Phase III study on treatment of hormone-refractory prostate cancer (HRPC) with docetaxel: continuous treatment vs. intermittent repetition of treatment after renewed progression—PRINCE. Urologe A. 2006;45(7):872.CrossRefGoogle Scholar
  31. 31.
    Kapoor A, Hotte SJ. Chemotherapy research for metastatic prostate cancer. Can Urol Assoc J. 2016;10(7-8Suppl3):S140–3.CrossRefGoogle Scholar
  32. 32.
    Cash H, Steiner U, Heidenreich A. PRINCE: a phase 3 study comparing intermittent docetaxel therapy vs. continuous docetaxel therapy in patients with castration-resistant prostate cancer. J Clin Oncol. 2016;34:Abstr 5005.Google Scholar
  33. 33.
    de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54.CrossRefGoogle Scholar
  34. 34.
    Nozawa M, Mukai H, Takahashi S, Uemura H, Kosaka T, Onozawa Y, et al. Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer. Int J Clin Oncol. 2015;20(5):1026–34.CrossRefGoogle Scholar
  35. 35.
    Omlin A, Sartor O, Rothermundt C, Cathomas R, De Bono JS, Shen L, et al. Analysis of side effect profile of alopecia, nail changes, peripheral neuropathy, and dysgeusia in prostate cancer patients treated with docetaxel and cabazitaxel. Clin Genitourin Cancer. 2015;13(4):e205–8.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Department of UrologyAkita University School of MedicineAkitaJapan

Personalised recommendations